Download The Findit App

Share Your Posts On These Major Social Networks

Instatag Your Posts to Instagram Facebook + Twitter

News

AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board

New York 2/3/2021 9:02:00 AM

AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Dr. Scott T. Tagawa, M.D., M.S., FACP, a Professor of Medicine and Urology at Weill Cornell Medicine and an Attending Physician at New York-Presbyterian-Weill Cornell Medical Center, has joined the Company's Scientific Advisory Board.

(PRNewsfoto/AIkido Pharma Incorporated)
(PRNewsfoto/AIkido Pharma Incorporated)

"Scott is a leading scholar in the field of oncology medicine and research," commented Mr. Anthony Hayes, CEO of AIkido. "His experience and expertise will be of tremendous value as we further our efforts to develop therapeutic treatments for cancer and leverage the technologies we have licensed. Dr. Tagawa is also the principle investigator for the targeted radiopharmaceutical therapy at Weil Cornell and his addition to our advisory board demonstrates our support for this innovative technology."

Dr. Scott T. Tagawa, MD, MS, FACP is a Professor of Medicine & Urology at Weill Cornell Medicine, and an Attending Physician at NewYork-Presbyterian – Weill Cornell Medical Center. Dr. Tagawa earned his BS from Georgetown University. He received his MD at the University of Southern California School of Medicine and after completing his internship and residency training there, he became Chief Resident. Subsequently, he underwent fellowship training in Hematology and Medical Oncology, being appointed Chief Fellow for his final two years.

 

In August 2005, Dr. Tagawa was appointed Assistant Professor of Medicine at Mount Sinai School of Medicine, serving as Associate Program Director for the Fellowship Training Program. As Director of Genitourinary Oncology for the Division of Hematology and Oncology and Director of Medical Oncology for the Deane Prostate Health and Research Center, Dr. Tagawa took the lead in developing genitourinary clinical trials.

Dr. Tagawa was recruited to Weill Cornell Medical College in 2007. His research covers clinical and translational investigations in genitourinary tumors and thrombosis in malignancy. As the Medical Director of the Genitourinary Oncology Research Program, Dr. Tagawa leads clinical trials in the areas of prostate, kidney and bladder cancer as well as the prevention and treatment of thrombosis with cancer. He specializes in drug development and theranostics in prostate cancer. Dr. Tagawa also serves as Associate Director of Clinical Research for the Division of Hematology and Medical Oncology and leader of the Genitourinary Disease Management Team of the Meyer Cancer Center. Dr. Tagawa is the WCMC principal investigator for the Alliance for Clinical Trials in Oncology (formerly CALGB), serving on the Board of Directors and as a funded member of the Genitourinary Committee. He is a member of the Clinical Practice Guidelines Committee of the American Society of Clinical Oncology (ASCO).

Additionally, he serves on the editorial boards of many journals, is a member of numerous national and international medical and scientific societies and has been named on multiple "top doctor" award lists.

About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:

Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.:

Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

More News

https://s3.amazonaws.com/findit-pictures/351133/5a9367a7-1d67-477a-8321-e8a4173d690f.jpg

Aikido Pharma Has Licensed DHA-dFdC at The University of Texas at Austin

Aikido Pharma Has Licensed DHA-dFdC at The University of Texas at Austin

Released On: 3/5/2021
Views: 446

https://s3.amazonaws.com/findit-pictures/351133/b9cc6d12-45b2-42d8-98c3-1ea2961eecad.jpg

Aikido Pharma Shares Published Papers and Articles on KPC-34 and DHA-dFdC

Aikido Pharma Shares Published Papers and Articles on KPC-34 and DHA-dFdC

Released On: 3/3/2021
Views: 429

https://s3.amazonaws.com/findit-pictures/351133/86c80767-4bb8-48ba-b5be-f5c6e1ff2d4d.jpg

Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin

Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin

Released On: 3/1/2021
Views: 443

https://s3.amazonaws.com/findit-pictures/351133/d1155add-3bd8-4751-8661-f9c48c2f069d.jpg

AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)

AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)

Released On: 3/1/2021
Views: 789

https://s3.amazonaws.com/findit-pictures/351133/48a25696-dac4-4e6d-bc52-6d181debb131.jpg

Meet Aikido Pharma Inc’s Board of Directors

Meet Aikido Pharma Inc’s Board of Directors

Released On: 2/28/2021
Views: 463

https://s3.amazonaws.com/findit-pictures/351133/06f2c09a-2436-4e6b-8eb3-f07578c8ab17.jpg

AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering

AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering

Released On: 2/23/2021
Views: 513

https://s3.amazonaws.com/findit-pictures/351133/bf0df713-8e2e-44ac-9609-f12bdf9847eb.jpg

Artificial Intelligence Is Optimizing Drug Development

Artificial Intelligence Is Optimizing Drug Development

Released On: 2/22/2021
Views: 521

https://s3.amazonaws.com/findit-pictures/351133/fad82173-54eb-4dcf-b365-5cf437598e16.jpg

Aikido Pharma Focuses on The Treatment of Four Main Types of Cancer

Aikido Pharma Focuses on The Treatment of Four Main Types of Cancer

Released On: 2/20/2021
Views: 415

https://s3.amazonaws.com/findit-pictures/351133/f5052f01-a9c3-48cf-8558-12b7f8dd5d85.jpg

AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock

AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock

Released On: 2/19/2021
Views: 570

https://s3.amazonaws.com/findit-pictures/351133/9642dc86-4305-4113-a789-78af0ea01972.jpg

AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million

AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million

Released On: 2/16/2021
Views: 656

https://s3.amazonaws.com/findit-pictures/351133/d64287af-b96d-47bb-a32b-65ddb76ff3d4.jpg

AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock

AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock

Released On: 2/16/2021
Views: 596

https://s3.amazonaws.com/findit-pictures/351133/54fa1d0c-edd2-4000-b922-08b0837dba1a.jpg

AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment

AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment

Released On: 2/16/2021
Views: 654

https://s3.amazonaws.com/findit-pictures/351133/d6d4252d-f996-436f-bf91-6c83af43e756.jpg

Aikido Pharma Announces Information on KPC-34 Which Was Developed at the Wake Forest School of Medicine

Aikido Pharma Announces Information on KPC-34 Which Was Developed at the Wake Forest School of Medicine

Released On: 2/15/2021
Views: 422

https://s3.amazonaws.com/findit-pictures/351133/8ac95bfe-f94b-4b9f-b39a-98d7aa7f6abd.jpg

Aikido Pharma Establishes Licensing Agreement with University of Maryland
for Antiviral Compounds, Including COVID-19

Aikido Pharma Establishes Licensing Agreement with University of Maryland
for Antiviral Compounds, Including COVID-19

Released On: 2/10/2021
Views: 342

https://s3.amazonaws.com/findit-pictures/351133/cdbebd8e-c86d-4537-8940-1b1b2ea0b06e.jpg

Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.

Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.

Released On: 2/9/2021
Views: 813

https://s3.amazonaws.com/findit-pictures/351133/09f4b098-397e-40d6-8af9-bacf930bb0cf.jpg

Aikido Pharma Secures Early Interest in Convergent Therapeutics, Inc. Who Focuses On Next Generation Radiopharmaceutical Therapy for Prostate Cancer

Aikido Pharma Secures Early Interest in Convergent Therapeutics, Inc. Who Focuses On Next Generation Radiopharmaceutical Therapy for Prostate Cancer

Released On: 2/5/2021
Views: 454

https://s3.amazonaws.com/findit-pictures/351133/59ca97a6-b0e3-47f3-adef-57939fddd0e5.jpg

AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board

AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board

Released On: 2/3/2021
Views: 1061

https://s3.amazonaws.com/findit-pictures/351133/e6e1220e-0686-4d01-8029-a87b9d54e412.jpg

Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics

Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics

Released On: 2/3/2021
Views: 536

Load More wait

Map

Aikido Pharma

Get Directions

Aikido Pharma

  • One Rockefeller Plaza
    New York, New York 10020
    United States
  • (212) 745-1373